Organon & Co. Reports $1.46 Billion Revenue, Net Income Rises to $146 Million in Q1 2026

Organon & Co. reported a revenue of $1.46 billion for the first quarter of 2026, a decrease of 4% compared to $1.51 billion in the same period of 2025. The company's net income rose to $146 million, or $0.55 per diluted share, up from $87 million, or $0.33 per diluted share, in the prior year. This increase in profitability was attributed to a net gain of $81 million from the divestiture of the Jada System, which was completed in January 2026. The effective income tax rate for the quarter was 31.4%, significantly higher than the 13.4% reported in the previous year, reflecting the impact of foreign earnings and U.S. tax regulations.

In terms of operational changes, Organon executed a strategic divestiture of the Jada System to Laborie Medical Technologies for up to $465 million, which included a contingent payment based on future sales. The company also entered into a licensing agreement with Sebela Pharmaceuticals for the global rights to Miudella, a hormone-free copper intrauterine device, with potential milestone payments totaling $505 million. These strategic moves are part of Organon's ongoing efforts to optimize its product portfolio and enhance its focus on women's health.

The company experienced a decline in sales across several key products, particularly Nexplanon, which saw a 19% drop in revenue due to decreased physician demand in the U.S. and shipment timing issues in emerging markets. Other products, such as Singulair and Ontruzant, also faced challenges due to competitive pressures and unfavorable market conditions. However, sales of biosimilars like Hadlima and Emgality showed significant growth, indicating a positive trend in certain segments of the portfolio.

Organon reported a total of 262.6 million shares outstanding as of April 27, 2026, and a cash position of $1.12 billion, reflecting a strong liquidity position. The company’s working capital increased to $2.43 billion, up from $1.96 billion at the end of 2025, aided by effective cash cycle management and the proceeds from the Jada divestiture. Looking ahead, Organon is focused on executing its strategic initiatives while navigating the complexities of the pharmaceutical market, including ongoing regulatory changes and competitive dynamics. The company is also preparing for a proposed merger with Sun Pharmaceutical Industries, which is subject to customary closing conditions and regulatory approvals, expected to close in early 2027.